• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by DiaMedica Therapeutics Inc. (Amendment)

    2/13/23 10:37:43 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DMAC alert in real time by email
    SC 13G/A 1 dmac13ga.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*

     

     

    DiaMedica Therapeutics Inc.

    (Name of Issuer)

     

     

    Voting common shares, no par value per share

    (Title of Class of Securities)

     

     

    25253X207

    (CUSIP Number)

     

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X]       Rule 13d-1(b)

     

    [ ]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. 25253X207

     

     

    1.Names of Reporting Persons.

    Timothy P. Lynch

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 100,259

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 100,259
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 100,259

     

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 0.4%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     2 
    CUSIP No. 25253X207

     

    Item 1.

     

    (a)Name of Issuer

    DiaMedica Therapeutics Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    301 Carlson Parkway, Suite 210, Minnetonka, Minnesota 55305

     

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Timothy P. Lynch

     

    (b)The principal business office of the Filers is located at

     

    919 NW Bond Street, Suite 204

    Bend, OR 97703-2767

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Voting common shares, no par value per share (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 25253X207

     

     3 
    CUSIP No. 25253X207
    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[ ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E).

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G).

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page for each Filer.

     

    The percentages reported in this Schedule 13G are based on 26,443,067 voting common shares outstanding as of November 7, 2022, as reported in the Issuer’s Form 10-Q filed on November 9, 2022.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.


    Item 10.
    Material to Be Filed as Exhibits

    Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.

    Item 11.Certification of Mr. Lynch

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 13, 2023

     

     

     

    /s/ Timothy P. Lynch

    Timothy P. Lynch

       
       
       

     

     4 
    CUSIP No. 25253X207

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Stonepine Capital Management, LLC, a California limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

    Dated: May 15, 2017

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By: /s/ Timothy P. Lynch
    Managing Member

     

     

    STONEPINE CAPITAL, L.P.

    By: Stonepine Capital Management, LLC,
    General Partner

    By: /s/ Timothy P. Lynch
    Managing Member

     

     
    /s/ Jon M. Plexico
     

     


    /s/ Timothy P. Lynch

     

     

    Get the next $DMAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DMAC

    DatePrice TargetRatingAnalyst
    10/7/2024$7.00Buy
    H.C. Wainwright
    4/24/2024$8.00Buy
    Craig Hallum
    6/22/2023$7.00Perform → Outperform
    Oppenheimer
    6/30/2021$38.00 → $32.00Buy
    Roth Capital
    More analyst ratings

    $DMAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company will participate in upcoming investor conferences in May 2025. 2025 RBC Capital Markets Global Healthcare Conference Tuesday, May 20th – Wednesday, May 21st, 2025, in New York City, New York. Management will be available for one-on-one meetings throughout the conference. H.C. Wainwright 3rd Annual BioConnect Conference Tuesday, May 20th, 2025, in New York City, New York. Management will participate in a fireside chat at 3:30 PM ET, which will be available via webcast at https://journey.ct.events/view/cb8

      5/8/25 4:00:00 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its first quarter 2025 financial results will be released after the markets close on Tuesday, May 13th. DiaMedica will host a live conference call on Wednesday, May 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Wednesday, May 14, 2025 Time: 8:00 AM ET / 7:00 AM CT Web access: https://app.webinar.net/24NpV0mjklG Dial In: (800) 836-8184 Conference ID: 93262 Interested parties may access the

      5/7/25 8:30:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

      Conference Call and Webcast March 18 at 8:00 AM Eastern Time / 7:00 AM Central Time  Preeclampsia Phase 2 Trial Preliminary Topline Safety and Efficacy Data from Part 1A of the Study Expected in the Second Quarter of 2025 Acute Ischemic Stroke Phase 2/3 Program Enrollment Ongoing Appointed Experienced Biotech Executive Daniel J. O'Connor to the Board Cash Runway into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the year ended December 31, 2024. Management will host a conference call Tuesday, M

      3/17/25 4:30:00 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by DiaMedica Therapeutics Inc.

      SC 13G - DiaMedica Therapeutics Inc. (0001401040) (Subject)

      7/8/24 5:23:49 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by DiaMedica Therapeutics Inc. (Amendment)

      SC 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)

      6/27/23 4:12:06 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by DiaMedica Therapeutics Inc. (Amendment)

      SC 13G/A - DiaMedica Therapeutics Inc. (0001401040) (Subject)

      6/27/23 4:11:32 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pilnik Richard D. exercised 24,000 units of Voting Common Shares at a strike of $2.11, increasing direct ownership by 8% to 312,995 units (SEC Form 4)

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      4/8/25 4:41:36 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director O'Connor Daniel J.

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      2/24/25 5:06:33 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider O'Connor Daniel J.

      3 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      2/24/25 4:54:22 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on DiaMedica Therapeutics with a new price target

      H.C. Wainwright initiated coverage of DiaMedica Therapeutics with a rating of Buy and set a new price target of $7.00

      10/7/24 7:50:42 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum resumed coverage on DiaMedica Therapeutics with a new price target

      Craig Hallum resumed coverage of DiaMedica Therapeutics with a rating of Buy and set a new price target of $8.00

      4/24/24 8:38:29 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded DiaMedica Therapeutics from Perform to Outperform and set a new price target of $7.00

      6/22/23 7:34:26 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Von Koch Thomas bought $3,000,000 worth of shares (1,200,000 units at $2.50) (SEC Form 4)

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      7/1/24 4:27:16 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Stahlberg Jan bought $3,000,000 worth of shares (1,200,000 units at $2.50) (SEC Form 4)

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      7/1/24 4:24:38 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wambeke David J. bought $49,200 worth of Voting Common Shares (20,000 units at $2.46), increasing direct ownership by 4% to 527,114 units (SEC Form 4)

      4 - DiaMedica Therapeutics Inc. (0001401040) (Issuer)

      11/16/23 4:37:28 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    SEC Filings

    See more
    • SEC Form DEFA14A filed by DiaMedica Therapeutics Inc.

      DEFA14A - DiaMedica Therapeutics Inc. (0001401040) (Filer)

      3/28/25 7:15:59 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by DiaMedica Therapeutics Inc.

      DEF 14A - DiaMedica Therapeutics Inc. (0001401040) (Filer)

      3/28/25 7:14:24 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by DiaMedica Therapeutics Inc.

      10-K - DiaMedica Therapeutics Inc. (0001401040) (Filer)

      3/17/25 4:32:31 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    Leadership Updates

    Live Leadership Updates

    See more
    • DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O'Connor to its Board of Directors, effective February 20, 2025. Mr. O'Connor has decades of executive experience and leadership in the biopharmaceutical industry, including as CEO and other executive level leadership positions at Ambrx Biopharma, Inc. (Ambrx), ImClone Systems Incorporated, Bracco Diagnostics, and PharmaNet (today, Syneos Health). Mr. O'Connor has gained a reputation as a seasoned and successful biopharma CEO, most recently serving as President, Chief Executive Officer and Director of Ambrx, wher

      2/24/25 8:30:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

      Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

      1/22/24 8:23:00 AM ET
      $DMAC
      $MRNS
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer

      Dr. Shah Has Spent Over Two Decades Leading Biological Development Teams at Biotechnology Companies and Has Deep Expertise in Protein Development and Manufacturing DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Ambarish Shah, Ph.D. as Chief Technology Officer. Dr. Shah will lead the development of DiaMedica's manufacturing operations for the late-stage drug candidate DM199. Since May 2023, Dr. Shah has been advising DiaMedica as it worked through the final resolution of the clinical hold on the investigational new drug applic

      9/12/23 8:13:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DMAC
    Financials

    Live finance-specific insights

    See more
    • DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its first quarter 2025 financial results will be released after the markets close on Tuesday, May 13th. DiaMedica will host a live conference call on Wednesday, May 14th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Wednesday, May 14, 2025 Time: 8:00 AM ET / 7:00 AM CT Web access: https://app.webinar.net/24NpV0mjklG Dial In: (800) 836-8184 Conference ID: 93262 Interested parties may access the

      5/7/25 8:30:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

      Conference Call and Webcast March 18 at 8:00 AM Eastern Time / 7:00 AM Central Time  Preeclampsia Phase 2 Trial Preliminary Topline Safety and Efficacy Data from Part 1A of the Study Expected in the Second Quarter of 2025 Acute Ischemic Stroke Phase 2/3 Program Enrollment Ongoing Appointed Experienced Biotech Executive Daniel J. O'Connor to the Board Cash Runway into Q3 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the year ended December 31, 2024. Management will host a conference call Tuesday, M

      3/17/25 4:30:00 PM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

      DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its full-year 2024 financial results will be released after the markets close on Monday, March 17th. DiaMedica will host a live conference call on Tuesday, March 18th at 7:00 AM Central Time to provide a business update and discuss financial results. Conference Call details: Date: Tuesday, March 18, 2025 Time: 7:00 AM CDT / 8:00 AM EDT Web access: https://app.webinar.net/yzor97w9Nvj Dial In: (800) 836-8184 Conference ID: 50034 Interested parties may access the conference call

      3/11/25 8:23:00 AM ET
      $DMAC
      Biotechnology: Pharmaceutical Preparations
      Health Care